Outcome of Board Meeting date 26th October 2026 and Unaudited Financial Results for the period ended on 30th September 2026.

VRL/SEC/EXCHANGE 26.10.2026 National Stock Exchange of India BSE Limited Ltd. 25th Floor, Phiroze Jeejeebhoy Towers 5th Floor, Exchange Plaza Dalal Street Bandra (E), Mumbai-400051 Mumbai-400051 Script Code: 526953 Script Code: VENUSREM Sub.: Outcome of Board Meeting date 26th October 2026 and Unaudited Financial Results for the period ended on 30th September 2026. Dear Sir/ Madam, This has reference to the meeting of Board of Directors held on 26th October 2026 inter alia considered and approved Unaudited Financial Results (Standalone and Consolidated) for the period ended on 30th September 2026 along with Limited Review report. Unaudited Financial Results for the period ended on 30th September 2026 along with the Limited Review report are enclosed herewith. Meeting commenced at 02:45 pin and concluded at 06:00 pin. Kindly take the above information on your record. Thanking you. Yours faithfully, for VENUS REMEDIES LIMITED Neha (Company Secretary) M.No. 8374 VENUS REMEDIES LIMITED Corpontc Cmc. : Unit-I : 51-52, Industnal Area, Phase-I, Panchkula (Hry.) i:I-.5:2+jT9]u7S±%3A3r6Sb?28Se3-5'9ErFC±¥S!F]%_23€5!.3'6`ndia 134113, India Regd. Once : t'hit-n : Hill Top lndustnal Estate, Jharmajri EPIP, Phase-I, (Extn.), SCO 857, Cabin No.10, 2nd Floor, NAG, Mamma]ra, Chandigarh (U.T.) 160101, India Ethfi°j;¥¥¥9'2P2a4d2di6%:P2'Li?8?°5J]nd]a Website : www.venusremedies.com Ualt-V : www.vlnrcindia.com emair : infe@venusremedies.com VENUS PHARMA GmbH ©EEt wh h E th gr AM Bahnhof I-3, D-59368, Weme , Ciermany Dun CuSTONS J.K. JAIN &ASSOCIATES CHARTERED ACCOUNTANTS S.C.O. 1136.31,SECTOR 22.B, CHANDIGARH - 160O22 4536-37 E01 -7 m2- a27 il0 jkjc aps@F ra ex d: i0 f f1 m72 a-2 i7 l.0 c o45 m37 Independent Auditor's Limited Review Report on Quarterly Unaudited Standalone Financial Results of Venus Remedies Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015t as amended The Board of Directors VENUS REMEDIES LIMITED 1. We have reviewed accompanying statement of unaudited standalone financial results of VENUS REMEDIES LIMITED ("the Company"), for the Quarter and half year ended 30tr' September 2026 ("the Statement"), being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. 2. This Statement which is responsibility of company's Management has been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standard 34 (Ind AS 34) for Interim Financial Reporting, prescribed, under Section 133 of the Companies Act,2013, as amended read with relevant rules issued thereunder; or by the Institute of Charlered Accountants of India, as applicable and other accounting principles generally accepted in India. The Statement has been approved by the Company's Board of Directors. Our responsibility is to report a conclusion on these statements based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the flnancial results are iree of material misstatement. A review of interim financial infbrmation consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accorclingly, we do not express an audit opinion. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited flnancial results prepared in accordance with applicable Indian accounting standards and other recognized accounting practices and policies has not disclosed the inlbrmation required to be disciosed in terms of Regulation 33 oflhe SEBI (Listing Obligations and Disclosure Requirements) Regulations,2015, as amended including the manner in which it is to be disclosed. or that it contains any material misstatement. Delhi Off. 503-504, Chiranjiv Tower 43, Nehru Place, New Emphasis of matter: 1. We draw attention to Note 5 of the accompanying Statement, which describes the outstanding share application money amounting to INR 2,859.72 Lakhs in respect of Venus Pharma GmbH, a wholly owned subsidiary of the Company. The share allotment against this amount has been pending and as per management representation it is not mandatory to allot under the applicable laws of Gennany Management has represented that they consider this investment strategic in nature and that the parent company intends to recover this amount in due course as a result of the restructuring of European operations carried out by the Management in FY 2026-27 . Although the subsidiary is currently facing financial challenges, the Company has reiterated its intention to provide the necessary financial and operational support during the transition period. Our conclusion is not modified in respect of these matters. ['or J.K Jain & Associates Chartered Accountants FRN-004025N CHARTERED FRN.004025N CA Anurag V Partner M. No. 555033 UDIN: 265s5033EA GZTF3448 Date: 26th Octoberr2026 CtN : L21002CH1989PLC009Z0S STATEMENT oF sTANDALoNE uNAUDTTED FTNANcTAL RESuLTS FoR THE QUARTER nno xalr vEAR ENDED oN 3OTH SEPTEMBER 2026 (Rs. ln Croree except EPS) S. No. PARTICULARS CIUARTER ENDED ON HALF YEAR ENOEO ON YEAR ENDED ON 30/09/2026 30/06/2026 30/09/2025 30/09/2025 30/09/2025 3110312rJ26 unaudited Unaudited Unaudited lJnaudited Unaudit6d Audited 1 Revenue (a) Revenue from Operations 218.76 178.80 192.65 397.55 329.78 768.73 (b) Other lncome 0.40 .EF 1.68 2.55 4.40 11.45 Total lncome 219.16 181.35 r94.33 400.50 334.18 780.19 2 Expenses (a) Cost of Material Consumed 97.39 83.14 106.51 180.53 177.84 387 (b) Purchase of stock in trade 2.13 1.12 1.87 3.26 4.13 10"76 (c) Changes in lnventories of finished goods, 6.73 0.02 (1.06) 6.75 (0.51) (11.47) work -in -progress & Stock in Trade (d) Employee benefits expense 25.82 22.56 22.03 48.38 41.29 84.85 (e) Depreciation & amortization expense oDa 6.51 5.92 15.78 11.87 (0 Selling ,Manufacturing and Administrative expenses 35.43 31.17 28.43 66.60 50.81 (g) Research & Development expenses 5.62 4.23 5.03 9.85 8.44 Total Expense r 82.39 148.75 168.73 331 .15 293.87 649.51 3 Profit bcfore taxes ( 't -2 ) 36.77 32.61 25.60 69.35 40.3,1 'r30.67 4 Exceptional ltems 5 Profit after exc€ptional items ( 3 + 4 l 36.77 32.61 25.60 69.35 40.3{ 130.67 EBIDTA (3+2e) 46.04 39.12 31.52 85.13 52.18 1 55.37 6 Tax Expen3ea A J,a! o,av 5.45 17.46 10.'t5 32.89 B Deferred Tax (1.44',t ({.{ 3) (0.0s) (2.57) (0.7e) (1.52) c Tax expense related to previous year 5 Profit before tax ( 3 +/- 4 ) 28.95 25.53 19.24 54.46 30.95 99.31 6 lncome Tax Expense /Defferred Tax( Benefits) 7 Nct Profit /( Loss) for the period (5 - 6) 28.96 25.53 19.24 54.4; 30.95 99.31 I Other Comprehenslve lncome A (l) ltems that will not be reclassified to Profit & loss 0.03 0.03 (0.r 2) 0.06 (0.24) 0.{ t B (l) ltems that may be reclassified to Profil & loss (0.46) 5.89 0.63 5.43 4,36 0.71 (ll) lncome tax relating to items that may be reclassified to Profit & ioe6 c Total other comprahensive Income Net of lncome Tax (0.43) 5.92 0.51 5.49 4.12 0.E3 I Total comprehenaive lncome for the period (7+/-8) 28.53 3{.45 ,t9.75 59.95 35.07 100.14 10 Paid up equity share capital 13.37 13.37 {3.37 {3.37 {3.37 13.37 ,: ,: ,: ( Face Vslue of Equity Sharss) 10 10 10 11 Other Equity 676.26 ,12 Earning per share ( of Rs. {0/- each ) (a) Basic (?) 21.56 19.10 14. [Showing first 8,000 characters — download PDF for full document]